AI assistant
TALPHERA, INC. — Director's Dealing 2019
Jun 25, 2019
35181_dirs_2019-06-25_9f47e353-8b83-4737-ba92-a1cdfa5d4eac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2019-06-25
Reporting Person: Rosen Howard B (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-06-25 | Common Stock | A | 3750 | $0.00 | Acquired | 61250 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-06-25 | Stock Option (Right to Buy) | $2.19 | A | 7500 | Acquired | 2029-06-25 | Common Stock (7500) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company.
F3: Balance includes non-reportable acquisition of 7,500 shares of Common Stock through the Company's Employee Stock Purchase Plan.
F4: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company.